Nancy Rusch
Concepts (303)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Calcium Channels, L-Type | 11 | 2017 | 67 | 2.300 |
Why?
| Muscle, Smooth, Vascular | 15 | 2020 | 130 | 2.170 |
Why?
| Hypertension | 11 | 2019 | 533 | 1.720 |
Why?
| Muscle Contraction | 5 | 2020 | 105 | 1.610 |
Why?
| Potassium Channels, Voltage-Gated | 5 | 2018 | 12 | 1.350 |
Why?
| Blood Pressure | 6 | 2018 | 512 | 1.110 |
Why?
| Calcium | 8 | 2017 | 396 | 1.060 |
Why?
| Mesenteric Arteries | 7 | 2014 | 45 | 0.980 |
Why?
| Lymphatic Vessels | 3 | 2020 | 48 | 0.980 |
Why?
| Myocytes, Smooth Muscle | 10 | 2020 | 86 | 0.920 |
Why?
| Large-Conductance Calcium-Activated Potassium Channels | 4 | 2015 | 12 | 0.870 |
Why?
| Coronary Vessels | 4 | 2017 | 152 | 0.850 |
Why?
| Up-Regulation | 5 | 2013 | 452 | 0.850 |
Why?
| Vasodilation | 8 | 2020 | 96 | 0.840 |
Why?
| Animals | 42 | 2024 | 13187 | 0.830 |
Why?
| Calcium Channels | 3 | 2008 | 46 | 0.800 |
Why?
| Rats | 22 | 2020 | 3305 | 0.730 |
Why?
| TRPM Cation Channels | 1 | 2019 | 4 | 0.700 |
Why?
| Potassium Channels, Tandem Pore Domain | 2 | 2011 | 12 | 0.690 |
Why?
| Ryanodine Receptor Calcium Release Channel | 1 | 2019 | 13 | 0.690 |
Why?
| Muscle Cells | 1 | 2019 | 22 | 0.680 |
Why?
| Lymph | 1 | 2019 | 19 | 0.680 |
Why?
| Cerebrovascular Circulation | 3 | 2020 | 132 | 0.680 |
Why?
| Cardiovascular Diseases | 3 | 2009 | 440 | 0.670 |
Why?
| Carotid Body | 1 | 2019 | 43 | 0.660 |
Why?
| Vasodilator Agents | 3 | 2009 | 96 | 0.640 |
Why?
| Cerebral Arteries | 5 | 2020 | 40 | 0.630 |
Why?
| Receptors, Adrenergic, beta | 1 | 2018 | 42 | 0.610 |
Why?
| Doxorubicin | 1 | 2019 | 233 | 0.600 |
Why?
| Cocaine | 1 | 2018 | 170 | 0.560 |
Why?
| Estradiol | 1 | 2017 | 225 | 0.540 |
Why?
| Arteries | 3 | 2005 | 93 | 0.520 |
Why?
| Vasoconstriction | 7 | 2014 | 54 | 0.510 |
Why?
| Mice, Knockout | 5 | 2024 | 841 | 0.510 |
Why?
| Ion Channels | 2 | 2023 | 72 | 0.510 |
Why?
| Cardiovascular Agents | 1 | 2015 | 54 | 0.500 |
Why?
| Retinal Diseases | 3 | 2024 | 49 | 0.490 |
Why?
| Membrane Potentials | 8 | 2014 | 117 | 0.480 |
Why?
| Rats, Sprague-Dawley | 13 | 2020 | 1597 | 0.470 |
Why?
| Gene Expression Regulation | 6 | 2019 | 976 | 0.470 |
Why?
| Blood Vessels | 2 | 2017 | 72 | 0.450 |
Why?
| Nifedipine | 2 | 2009 | 25 | 0.410 |
Why?
| Calcium Channel Blockers | 2 | 2009 | 62 | 0.390 |
Why?
| Angiotensin II | 1 | 2012 | 157 | 0.390 |
Why?
| Aorta | 2 | 2011 | 161 | 0.380 |
Why?
| Aging | 3 | 2023 | 687 | 0.380 |
Why?
| Patch-Clamp Techniques | 9 | 2015 | 124 | 0.370 |
Why?
| Endothelial Cells | 2 | 2023 | 269 | 0.370 |
Why?
| Shaker Superfamily of Potassium Channels | 4 | 2014 | 10 | 0.360 |
Why?
| Genetic Therapy | 2 | 2008 | 114 | 0.360 |
Why?
| Drug Resistance | 1 | 2009 | 63 | 0.350 |
Why?
| Coronary Circulation | 1 | 2009 | 57 | 0.340 |
Why?
| Mice, Inbred C57BL | 6 | 2024 | 1816 | 0.320 |
Why?
| Vascular Resistance | 3 | 2017 | 54 | 0.320 |
Why?
| Potassium Channels | 2 | 2005 | 31 | 0.310 |
Why?
| alpha-Linolenic Acid | 1 | 2007 | 2 | 0.300 |
Why?
| Hypertension, Pulmonary | 1 | 2008 | 114 | 0.280 |
Why?
| Cerebellum | 1 | 2007 | 135 | 0.270 |
Why?
| Down-Regulation | 2 | 2008 | 348 | 0.270 |
Why?
| Reperfusion Injury | 2 | 2024 | 87 | 0.270 |
Why?
| Mice | 11 | 2024 | 5739 | 0.270 |
Why?
| Endothelium, Vascular | 3 | 2022 | 252 | 0.270 |
Why?
| Brain Ischemia | 1 | 2007 | 161 | 0.260 |
Why?
| Serotonin | 4 | 2013 | 152 | 0.260 |
Why?
| Calcium Signaling | 3 | 2013 | 56 | 0.250 |
Why?
| Dose-Response Relationship, Drug | 3 | 2019 | 1376 | 0.240 |
Why?
| Histone Deacetylases | 1 | 2024 | 50 | 0.230 |
Why?
| beta Catenin | 1 | 2024 | 102 | 0.220 |
Why?
| Wnt Signaling Pathway | 1 | 2024 | 92 | 0.220 |
Why?
| Cells, Cultured | 4 | 2020 | 1573 | 0.220 |
Why?
| Diabetic Retinopathy | 1 | 2024 | 40 | 0.220 |
Why?
| Gene Expression | 2 | 2002 | 609 | 0.220 |
Why?
| Potassium Channels, Calcium-Activated | 1 | 2002 | 5 | 0.220 |
Why?
| Macrophages | 2 | 2024 | 363 | 0.220 |
Why?
| Humans | 20 | 2024 | 49974 | 0.210 |
Why?
| Protons | 1 | 2023 | 69 | 0.210 |
Why?
| Swine | 2 | 2017 | 393 | 0.210 |
Why?
| RNA, Messenger | 5 | 2009 | 1105 | 0.200 |
Why?
| Feedback, Physiological | 1 | 2002 | 12 | 0.200 |
Why?
| Intracellular Signaling Peptides and Proteins | 2 | 2014 | 142 | 0.200 |
Why?
| TRPC Cation Channels | 2 | 2020 | 21 | 0.200 |
Why?
| Carcinoma, Hepatocellular | 1 | 2024 | 191 | 0.200 |
Why?
| Blotting, Western | 6 | 2011 | 601 | 0.200 |
Why?
| KATP Channels | 1 | 2020 | 6 | 0.190 |
Why?
| Adrenergic beta-1 Receptor Antagonists | 1 | 2020 | 6 | 0.190 |
Why?
| Receptors, Adrenergic, beta-1 | 1 | 2020 | 7 | 0.190 |
Why?
| Large-Conductance Calcium-Activated Potassium Channel alpha Subunits | 3 | 2019 | 6 | 0.190 |
Why?
| Epigenesis, Genetic | 1 | 2024 | 374 | 0.190 |
Why?
| Metoprolol | 1 | 2020 | 13 | 0.190 |
Why?
| Membrane Proteins | 2 | 2014 | 341 | 0.180 |
Why?
| Liver Neoplasms | 1 | 2024 | 326 | 0.180 |
Why?
| Cardiotonic Agents | 1 | 2020 | 66 | 0.180 |
Why?
| Male | 16 | 2023 | 25241 | 0.180 |
Why?
| Mitochondria | 2 | 2023 | 402 | 0.180 |
Why?
| Thiourea | 1 | 2019 | 9 | 0.180 |
Why?
| Edema | 1 | 2020 | 67 | 0.180 |
Why?
| Kidney Tubules, Proximal | 1 | 2019 | 62 | 0.170 |
Why?
| Tetrazoles | 1 | 2019 | 41 | 0.170 |
Why?
| Organ Culture Techniques | 1 | 2019 | 48 | 0.170 |
Why?
| Protein Subunits | 3 | 2008 | 77 | 0.170 |
Why?
| Status Epilepticus | 1 | 2020 | 39 | 0.170 |
Why?
| Antibiotics, Antineoplastic | 1 | 2019 | 78 | 0.160 |
Why?
| Leptin | 1 | 2019 | 140 | 0.160 |
Why?
| Malate Dehydrogenase | 1 | 2018 | 8 | 0.160 |
Why?
| Vascular Stiffness | 1 | 2018 | 18 | 0.150 |
Why?
| Rats, Inbred WKY | 3 | 2009 | 27 | 0.150 |
Why?
| Rats, Inbred SHR | 3 | 2009 | 35 | 0.150 |
Why?
| Microscopy | 1 | 2018 | 56 | 0.150 |
Why?
| Ion Channel Gating | 2 | 2008 | 39 | 0.150 |
Why?
| Estrogen Receptor beta | 1 | 2017 | 54 | 0.150 |
Why?
| Estrogen Receptor alpha | 1 | 2017 | 89 | 0.140 |
Why?
| Potassium Chloride | 2 | 2009 | 20 | 0.140 |
Why?
| Muscle, Skeletal | 1 | 2002 | 750 | 0.140 |
Why?
| Thioredoxins | 1 | 2017 | 24 | 0.140 |
Why?
| Nitric Oxide Synthase Type III | 1 | 2017 | 78 | 0.140 |
Why?
| Reactive Oxygen Species | 1 | 2018 | 408 | 0.130 |
Why?
| Signal Transduction | 3 | 2014 | 1618 | 0.120 |
Why?
| Delayed Rectifier Potassium Channels | 2 | 2005 | 2 | 0.120 |
Why?
| Pressoreceptors | 1 | 2014 | 7 | 0.120 |
Why?
| Renal Artery | 1 | 2014 | 33 | 0.120 |
Why?
| Hemodynamics | 2 | 2008 | 228 | 0.120 |
Why?
| Myeloid Cells | 2 | 2024 | 38 | 0.120 |
Why?
| MicroRNAs | 1 | 2018 | 353 | 0.120 |
Why?
| Receptor, Angiotensin, Type 1 | 1 | 2014 | 57 | 0.120 |
Why?
| Inositol 1,4,5-Trisphosphate Receptors | 1 | 2013 | 9 | 0.120 |
Why?
| Urinalysis | 1 | 2014 | 34 | 0.120 |
Why?
| Sex Characteristics | 1 | 2015 | 190 | 0.120 |
Why?
| Cyclic AMP-Dependent Protein Kinases | 1 | 2014 | 51 | 0.110 |
Why?
| Flow Cytometry | 2 | 2013 | 476 | 0.110 |
Why?
| Fentanyl | 1 | 2014 | 36 | 0.110 |
Why?
| Retina | 2 | 2024 | 64 | 0.110 |
Why?
| Polysaccharides | 1 | 2013 | 50 | 0.110 |
Why?
| Platelet Aggregation | 1 | 2013 | 71 | 0.110 |
Why?
| Cerebrospinal Fluid | 1 | 2013 | 32 | 0.110 |
Why?
| Cell Dedifferentiation | 1 | 2012 | 9 | 0.110 |
Why?
| Carotid Arteries | 2 | 2017 | 85 | 0.110 |
Why?
| Ischemia | 2 | 2024 | 153 | 0.110 |
Why?
| Neoplastic Cells, Circulating | 1 | 2013 | 74 | 0.100 |
Why?
| Photoacoustic Techniques | 1 | 2013 | 72 | 0.100 |
Why?
| Temperature | 1 | 2013 | 168 | 0.100 |
Why?
| Vascular System Injuries | 1 | 2012 | 36 | 0.100 |
Why?
| Cell Membrane | 2 | 2013 | 248 | 0.100 |
Why?
| Regional Blood Flow | 2 | 2014 | 108 | 0.100 |
Why?
| Potassium | 2 | 2020 | 57 | 0.100 |
Why?
| Cell Line | 4 | 2019 | 1000 | 0.100 |
Why?
| Post-Synaptic Density | 1 | 2011 | 4 | 0.100 |
Why?
| Microcirculation | 2 | 2009 | 70 | 0.100 |
Why?
| Enzyme Inhibitors | 2 | 2014 | 391 | 0.100 |
Why?
| Cell Movement | 1 | 2012 | 247 | 0.100 |
Why?
| Nanoparticles | 1 | 2013 | 145 | 0.100 |
Why?
| Stem Cells | 1 | 2012 | 171 | 0.100 |
Why?
| Bacteria | 1 | 2013 | 224 | 0.100 |
Why?
| Vasoconstrictor Agents | 2 | 2009 | 84 | 0.100 |
Why?
| Obesity | 1 | 2019 | 1113 | 0.100 |
Why?
| Muscle Proteins | 1 | 2013 | 303 | 0.090 |
Why?
| Phenotype | 2 | 2012 | 729 | 0.090 |
Why?
| Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2009 | 8 | 0.090 |
Why?
| Mesenteric Veins | 1 | 2009 | 13 | 0.090 |
Why?
| Chelating Agents | 1 | 2009 | 27 | 0.090 |
Why?
| Large-Conductance Calcium-Activated Potassium Channel beta Subunits | 1 | 2009 | 1 | 0.090 |
Why?
| Arterioles | 1 | 2009 | 33 | 0.090 |
Why?
| Hypertension, Renovascular | 1 | 2009 | 14 | 0.080 |
Why?
| Vimentin | 1 | 2009 | 32 | 0.080 |
Why?
| Potassium Channel Blockers | 2 | 2011 | 16 | 0.080 |
Why?
| Serotonin Plasma Membrane Transport Proteins | 1 | 2009 | 47 | 0.080 |
Why?
| Pulmonary Circulation | 1 | 2008 | 33 | 0.080 |
Why?
| Cell Proliferation | 1 | 2012 | 1007 | 0.080 |
Why?
| Analgesics, Opioid | 1 | 2014 | 552 | 0.080 |
Why?
| Phosphorylation | 3 | 2017 | 535 | 0.080 |
Why?
| Molecular Mimicry | 1 | 2008 | 38 | 0.080 |
Why?
| Action Potentials | 2 | 2020 | 132 | 0.080 |
Why?
| Laser-Doppler Flowmetry | 1 | 2007 | 16 | 0.080 |
Why?
| Genetic Vectors | 1 | 2008 | 125 | 0.070 |
Why?
| Animals, Newborn | 1 | 2008 | 367 | 0.070 |
Why?
| Blood Flow Velocity | 1 | 2007 | 101 | 0.070 |
Why?
| Drug Design | 1 | 2008 | 120 | 0.070 |
Why?
| Pulmonary Artery | 1 | 2008 | 145 | 0.070 |
Why?
| Recombinant Fusion Proteins | 1 | 2008 | 181 | 0.070 |
Why?
| Disease Models, Animal | 2 | 2024 | 1455 | 0.070 |
Why?
| Mice, Transgenic | 2 | 2020 | 555 | 0.070 |
Why?
| Chronic Disease | 1 | 2008 | 567 | 0.070 |
Why?
| Cell Line, Tumor | 2 | 2024 | 1403 | 0.060 |
Why?
| Protein Conformation | 1 | 2006 | 166 | 0.060 |
Why?
| Mutation | 2 | 2009 | 1294 | 0.060 |
Why?
| Anterior Cerebral Artery | 1 | 2005 | 4 | 0.060 |
Why?
| 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid | 1 | 2005 | 4 | 0.060 |
Why?
| Cannabinoid Receptor Modulators | 1 | 2005 | 11 | 0.060 |
Why?
| Myocardium | 1 | 2008 | 436 | 0.060 |
Why?
| Endocannabinoids | 1 | 2005 | 23 | 0.060 |
Why?
| Antihypertensive Agents | 1 | 2006 | 117 | 0.060 |
Why?
| Lung | 1 | 2008 | 486 | 0.060 |
Why?
| Gene Expression Profiling | 1 | 2009 | 1032 | 0.060 |
Why?
| Culture Techniques | 1 | 2004 | 20 | 0.060 |
Why?
| Phagocytosis | 1 | 2024 | 48 | 0.060 |
Why?
| Sp1 Transcription Factor | 1 | 2024 | 21 | 0.060 |
Why?
| Nitrogen | 1 | 2004 | 66 | 0.060 |
Why?
| Ornithine Decarboxylase | 1 | 2023 | 12 | 0.060 |
Why?
| Ornithine | 1 | 2023 | 16 | 0.060 |
Why?
| Kv1.3 Potassium Channel | 1 | 2003 | 1 | 0.060 |
Why?
| Kv1.4 Potassium Channel | 1 | 2003 | 1 | 0.060 |
Why?
| Kv1.1 Potassium Channel | 1 | 2003 | 2 | 0.060 |
Why?
| Kv1.5 Potassium Channel | 1 | 2003 | 2 | 0.060 |
Why?
| Kv1.2 Potassium Channel | 1 | 2003 | 2 | 0.060 |
Why?
| Arginase | 1 | 2023 | 35 | 0.060 |
Why?
| Protein Structure, Quaternary | 1 | 2003 | 26 | 0.060 |
Why?
| Triterpenes | 1 | 2003 | 11 | 0.060 |
Why?
| Calcium Channel Agonists | 1 | 2002 | 3 | 0.050 |
Why?
| 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester | 1 | 2002 | 9 | 0.050 |
Why?
| Endothelins | 1 | 2002 | 17 | 0.050 |
Why?
| Chromatography, Liquid | 2 | 2014 | 232 | 0.050 |
Why?
| Mitochondrial Proteins | 1 | 2023 | 90 | 0.050 |
Why?
| Transcription, Genetic | 2 | 2014 | 369 | 0.050 |
Why?
| Cattle | 1 | 2002 | 210 | 0.050 |
Why?
| Glucose | 1 | 2004 | 344 | 0.050 |
Why?
| Adenosine Triphosphate | 1 | 2023 | 233 | 0.050 |
Why?
| Femoral Artery | 1 | 2002 | 100 | 0.050 |
Why?
| Tumor Necrosis Factor-alpha | 1 | 2023 | 388 | 0.050 |
Why?
| NF-kappa B | 1 | 2023 | 314 | 0.050 |
Why?
| Cromakalim | 1 | 2020 | 4 | 0.050 |
Why?
| Adrenergic beta-1 Receptor Agonists | 1 | 2020 | 3 | 0.050 |
Why?
| Minoxidil | 1 | 2020 | 5 | 0.050 |
Why?
| Diazoxide | 1 | 2020 | 6 | 0.050 |
Why?
| Dobutamine | 1 | 2020 | 16 | 0.050 |
Why?
| Cytokines | 1 | 2023 | 612 | 0.050 |
Why?
| Norepinephrine | 1 | 2020 | 107 | 0.040 |
Why?
| Pentylenetetrazole | 1 | 2020 | 9 | 0.040 |
Why?
| Pilocarpine | 1 | 2020 | 25 | 0.040 |
Why?
| Gene Expression Regulation, Neoplastic | 1 | 2024 | 828 | 0.040 |
Why?
| Membrane Potential, Mitochondrial | 1 | 2019 | 38 | 0.040 |
Why?
| Cryopreservation | 1 | 2019 | 31 | 0.040 |
Why?
| Heart Rate | 1 | 2020 | 293 | 0.040 |
Why?
| Blood Platelets | 2 | 2013 | 245 | 0.040 |
Why?
| Epithelial Cells | 1 | 2019 | 209 | 0.040 |
Why?
| Electroencephalography | 1 | 2020 | 306 | 0.040 |
Why?
| Mesenteric Artery, Superior | 1 | 2017 | 10 | 0.040 |
Why?
| Superoxides | 1 | 2017 | 46 | 0.040 |
Why?
| Female | 1 | 2017 | 26472 | 0.040 |
Why?
| Image Processing, Computer-Assisted | 1 | 2018 | 242 | 0.030 |
Why?
| Models, Biological | 1 | 2019 | 727 | 0.030 |
Why?
| Aorta, Thoracic | 1 | 2017 | 92 | 0.030 |
Why?
| Oxidation-Reduction | 1 | 2017 | 322 | 0.030 |
Why?
| Glutathione | 1 | 2017 | 295 | 0.030 |
Why?
| Microscopy, Immunoelectron | 1 | 2015 | 11 | 0.030 |
Why?
| Recombinant Proteins | 1 | 2017 | 486 | 0.030 |
Why?
| Genes, Reporter | 1 | 2015 | 89 | 0.030 |
Why?
| 4-Aminopyridine | 1 | 2014 | 3 | 0.030 |
Why?
| GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2014 | 6 | 0.030 |
Why?
| Anthracenes | 1 | 2014 | 9 | 0.030 |
Why?
| Osmotic Pressure | 1 | 2014 | 10 | 0.030 |
Why?
| KCNQ Potassium Channels | 1 | 2014 | 3 | 0.030 |
Why?
| KCNQ3 Potassium Channel | 1 | 2014 | 4 | 0.030 |
Why?
| Hemorheology | 1 | 2014 | 11 | 0.030 |
Why?
| Losartan | 1 | 2014 | 26 | 0.030 |
Why?
| Peptides | 1 | 2015 | 223 | 0.030 |
Why?
| Myocytes, Cardiac | 1 | 2015 | 125 | 0.030 |
Why?
| Angiotensin II Type 1 Receptor Blockers | 1 | 2014 | 43 | 0.030 |
Why?
| N-Acetylneuraminic Acid | 1 | 2013 | 12 | 0.030 |
Why?
| NFATC Transcription Factors | 1 | 2013 | 23 | 0.030 |
Why?
| Chemical Fractionation | 1 | 2013 | 17 | 0.030 |
Why?
| Mixed Function Oxygenases | 1 | 2013 | 25 | 0.030 |
Why?
| HEK293 Cells | 1 | 2014 | 222 | 0.030 |
Why?
| Mammary Neoplasms, Animal | 1 | 2013 | 35 | 0.030 |
Why?
| Models, Animal | 1 | 2014 | 233 | 0.030 |
Why?
| Spectrum Analysis | 1 | 2013 | 70 | 0.030 |
Why?
| Staining and Labeling | 1 | 2013 | 97 | 0.030 |
Why?
| Molecular Imaging | 1 | 2013 | 53 | 0.030 |
Why?
| Cytochrome P-450 Enzyme System | 1 | 2014 | 195 | 0.030 |
Why?
| Calcineurin | 1 | 2013 | 71 | 0.030 |
Why?
| Cell Lineage | 1 | 2012 | 83 | 0.030 |
Why?
| Tandem Mass Spectrometry | 1 | 2014 | 236 | 0.030 |
Why?
| Mass Spectrometry | 1 | 2013 | 306 | 0.030 |
Why?
| Extracellular Matrix | 1 | 2012 | 111 | 0.030 |
Why?
| Gold | 1 | 2013 | 136 | 0.030 |
Why?
| Spider Venoms | 1 | 2011 | 6 | 0.020 |
Why?
| Oligonucleotides, Antisense | 1 | 2011 | 28 | 0.020 |
Why?
| Brain | 1 | 2020 | 1328 | 0.020 |
Why?
| Gene Knockdown Techniques | 1 | 2011 | 106 | 0.020 |
Why?
| Time Factors | 1 | 2018 | 2903 | 0.020 |
Why?
| Real-Time Polymerase Chain Reaction | 1 | 2011 | 181 | 0.020 |
Why?
| Acetylcholine | 1 | 2009 | 54 | 0.020 |
Why?
| Biotinylation | 1 | 2009 | 26 | 0.020 |
Why?
| Chromatography, Affinity | 1 | 2009 | 38 | 0.020 |
Why?
| Fluorescent Antibody Technique | 1 | 2009 | 108 | 0.020 |
Why?
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2009 | 63 | 0.020 |
Why?
| Protein Engineering | 1 | 2008 | 18 | 0.020 |
Why?
| Peptide Fragments | 1 | 2009 | 215 | 0.020 |
Why?
| DNA, Complementary | 1 | 2008 | 135 | 0.020 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 595 | 0.020 |
Why?
| Drug Delivery Systems | 1 | 2008 | 138 | 0.020 |
Why?
| Diglycerides | 1 | 2005 | 9 | 0.020 |
Why?
| Phosphatidylethanolamines | 1 | 2005 | 11 | 0.020 |
Why?
| Isoindoles | 1 | 2004 | 2 | 0.020 |
Why?
| Organoselenium Compounds | 1 | 2004 | 2 | 0.020 |
Why?
| Free Radical Scavengers | 1 | 2004 | 25 | 0.020 |
Why?
| Uric Acid | 1 | 2004 | 21 | 0.020 |
Why?
| Peroxynitrous Acid | 1 | 2004 | 32 | 0.020 |
Why?
| Azoles | 1 | 2004 | 28 | 0.020 |
Why?
| Desoxycorticosterone | 1 | 2002 | 6 | 0.010 |
Why?
| Receptor, Endothelin A | 1 | 2002 | 8 | 0.010 |
Why?
| Receptors, Endothelin | 1 | 2002 | 7 | 0.010 |
Why?
| Osmolar Concentration | 1 | 2002 | 62 | 0.010 |
Why?
| Endothelin-1 | 1 | 2002 | 31 | 0.010 |
Why?
| Sodium Chloride | 1 | 2002 | 57 | 0.010 |
Why?
|
|
Rusch's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|